Читать книгу Hypopharyngeal Cancer - Группа авторов - Страница 40

1Tsikoudas A, Ghuman N, Riad MA: Globus sensation as early presentation of hypopharyngeal cancer. Clin Otolaryngol 2007; 32: 452–456.

2Soon SR, Kanagalingam J, Johari S, Yuen HW: Head and Neck Cancers masquerading as deep neck abscesses. Singapore Med J 2012; 53: 840–842.

3Lin YY, Hsu CH, Lee JC, et al: Head and neck cancers manifested as deep neck infection. Eur Arch Otorhinolaryngol 2012; 269: 585–590.

4Heng PS, Irfan M: Hypopharyngeal cancer masquerading as a thyroid mass. Med J Malaysia 2016; 71: 360–362.

5Alaani A, Vengala S, Johnston MN: The role of barium swallow in the management of the globus pharyngeus. Eur Arch Otorhinolaryngol 2007; 284: 1095–1097.

6Galmiche JP, Clouse RE, Balint A, et al: Functional esophageal disorders. Gastroenterology 2006; 130: 1459–1465.

7Karkos PD, Wilson JA: The diagnosis and management of globus pharyngeus: our perspective from the United Kingdom. Curr Opin Otolaryngol Head Neck Surg 2008; 16: 521–524.

8Doody J, Fenton JE: Troublesome Throat Awareness (tTA) as a contemporary alternative to “globus pharyngeus”. Surgeon 2017; 15: 15: 183–185.

9Rowley H, O’Dwyer TP, Jones AS, Timon CI: The natural history of globus pharyngeus. Laryngoscope 1996; 105: 1118–1121.

10Abou-Nader L, Wilson JA, Paleri V: Transnasal oesophagoscopy: diagnostic and management outcomes in a prospective cohort of 257 consecutive cases and practice implications. Clin Otolaryngol 2014; 39: 108–113.

11Fenton JE, Hone S, Gormley P, et al: Hypopharyngeal tumours may be missed on flexible oesophagogastroscopy. BMJ 1995; 311: 623–624.

12Brierly JD, Gospodarowicz MK, Wittekind C (eds): TNM Classification of Malignant Tumours: Union of International Cancer Control (UICC), 8th edition. Oxford, Wiley Blackwell, 2017.

13Amin MB, Edge S, Greene F, et al: in Amin AB, Edge SB, Greene FL (eds): American Joint Cancer Committee, Cancer Staging Manual, 8th edition. New York, Springer, 2017.

14Sobin LH: TNM: principles, history, and relation to other prognostic factors. Cancer 2001; 91: 1589–1592.

15Denoix PF: Tumor, node and metastasis (TNM). Bull Inst Nat Hyg (Paris) 1944; 1: 1–69.

16O’Sullivan B, Shah JP: Chapter 8: head and neck cancer staging and prognosis: perspectives of the UICC and the AJCC; in Bernier J (ed): Head and Neck Cancer. New York, Springer, 2011.

17Patel SG, Shah JP: TNM Staging of cancers of the head and neck: striving for uniformity amongst diversity. CA Cancer J Clin 2005; 55: 242–258.

18Lydiatt WM, Patel SG, O’Sullivan B, et al: Head and neck cancers-Major changes in the American Joint Committee on cancer eighth edition cancer staging manual. CA Cancer J Clin 2017; 67: 122–137.

19Kuperman DI, Auethavekiat V, Adkins DR, et al: Squamous cell cancer of the head and neck with distant metastasis at presentation. Head Neck 2011; 33: 714–718.

20Takes RP, Rinaldo A, Silver CE, et al: Distant metastases from head and neck squamous cell carcinoma. Part I. Basic aspects. Oral Oncol 2012; 48: 775–779.

21Leon X, Quer M, Orus C, et al: Distant metastases in head and neck cancer patients who achieved loco-regional control. Head Neck 2000; 22: 680–686.

22Caballero M, Vilaseca I, Bernal-Sprakelsen M, et al: Distant metastasis after transoral laser microsurgery for laryngeal and hypopharyngeal squamous cell carcinoma. Head Neck 2008; 30: 1599–1606.

23Takes RP, Strojan P, Silver CE, et al: Current trends in initial management of hypopharyngeal cancer: the declining use of open surgery. Head Neck 2012; 34: 270–281.

24Olzowy R, Hillebrand M, Harreus U: Frequency of bilateral cervical metastases in hypopharyngeal squamous cell carcinoma: a retrospective analysis of 203 cases after bilateral neck dissection. Eur Arch Otorhinolaryngol 2017; 274: 3865–3970.

25Wu Z, Deng XY, Zeng RF, et al: Analysis of risk factors for retropharyngeal lymph node metastasis in carcinoma of the hypopharynx. Head Neck 2013; 35: 1274–1277.

26Jon YH, Sun DI, Cho KJ, et al: The impact of paratracheal lymph node metastasis in squamous cell carcinoma of the hypopharynx. Eur Arch Otorhinolaryngol 2010; 267: 945–950.

27Patel SG, Lydiatt WM: Staging of head and neck cancers: is it time to change the balance between the ideal and the practical? J Surg Oncol 2008; 97: 653–657.

28Hall SF, Groome PA, Irish J, O’Sullivan B: TNM-based stage groupings in head and neck cancer: application in cancer of the hypopharynx. Head Neck 2009; 31: 1–8.

29Takes RP, Rinaldo A, Silver CE, et al: Future of the TNM classification and staging system in head and neck cancer. Head Neck 2010; 32: 1693–1711.

30Hodul PJ, Yeatman TJ: TNM Staging is Obsolete. J Surg Oncol 2007; 95: 8–9.

31Tsou YA, Hua JH, Lin MH, Tsai MH: Analysis of prognostic factors of chemoradiation therapy for advanced hypopharyngeal cancer – does tumor volume correlate with central necrosis and tumor pathology? ORL 2006; 68: 206–212.

32Chong VF: Tumour volume measurement in head and neck cancer. Cancer Imaging 2007; 7:S47–S49.

33Studer G, Lutolf M, El-Bassionuni M, et al: Volumetric staging (VS) is superior to TNM and AJCC staging in predicting outcome of head and neck cancer treated with IMRT. Acta Oncol 2007; 46: 386–394.

34Doweek I, Denys D, Robbins KT: Tumor volume predicts outcome for advanced head and neck cancer treated with targeted chemoradiotherapy. Laryngoscope 2002; 112: 1742–1749.

35Caldas-Magalhaes J, Kooij N, et al: The accuracy of target delineation in laryngeal and hypopharyngeal cancer. Acta Oncol 2015; 54: 1181–1187.

36Farina E, Ferioli M, Castellucci P, et al: ¹⁸F-Fdg-PET-guided planning and re-planning (adaptive) radiotherapy in head and neck cancer: Current state of art. Anticancer Res 2017; 37: 6523–6532.

37Kawashima M, Hayashi R, Tahara M, et al: Prospective trial of chemotherapy-enhanced accelerated radiotherapy for larynx preservation in patients with intermediate-volume hypopharyngeal cancer. Head Neck 2012; 34; 1363–1368.

38Chen SW, Yang SN, Liang JA, et al: Prognostic impact of tumor volume in patients with stage III–IVA hypopharyngeal cancer without bulk lymph nodes treated with definitive concurrent chemoradiotherapy. Head Neck 2009; 31: 709–716.

39Genther DJ, Gourin CG: Effect of comorbidity on short-term outcomes and cost of care after head and neck cancer surgery. Head Neck 2015; 37: 685–693.

40Boje CR: Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma – a systematic review. Radiother Oncol 2014; 110: 81–90.

41Paleri V, Eight RG, Silver CE, Haigentz M Jr, et al: Comorbidity in head and neck cancer: a critical appraisal and recommendations for practice. Oral Oncol 2010; 46: 712–719.

42Charlson M, Szatrowski TP, Peterson J, Gold J: Validation of a combined comorbidity index. J Clin Epidemiol 1994; 47: 1245–1251.

43Clemens JD, Feinstein AR, Holabird N, Cartwright SA: A new clinical-anatomic staging system for evaluating prognosis and treatment of prostate cancer. J Chronic Dis 1986; 39: 913–928.

44Homma A, Sakashita T, Oridate N, et al: Importance of comorbidity in hypopharyngeal cancer. Head Neck 2010; 32: 148–153.

45Tanakka H, Takenaka Y, Nakahara S, et al: Age-related Charlson comorbidity index as a prognostic factor of hypopharyngeal cancer treated with chemoradiotherapy. Acta Oto Laryngologica 2017; 137: 668–673.

46Raghavan U, Quraishi S, Bradley PJ: Multiple primary tumours in patients diagnosed with hypopharyngeal cancer. Otolaryngol Head Neck Surg 2003; 128: 419–425.

47Lee DH, Lu CH, Chen PT, et al: The incidence and risk of developing a second primary oesophageal cancer in patients with oral and pharyngeal carcinoma; a population based study in Taiwan over a 25-year period. BMC Cancer 2009; 9: 373.

48Chuang S-C, Scelo G, Tonita JM, et al: Risk of second primary cancer among patients with head and neck cancers: a pooled analysis of 13 cancer registries. Int J Cancer 2008; 123: 2390–2396.

49Liu WS, Chang YJ, Lin CL, et al: Secondary primary cancer in patients with head and neck carcinoma: the differences among hypopharyngeal, laryngeal, and other sites of head and neck cancer. Eur J Cancer Care (Engl) 2014; 23: 36–42.

50Milano MT, Peterson CR 3rd, Zhang H, et al: Second primary lung cancer after head and neck squamous cell cancer: population-based study of risk factors. Head Neck 2012; 34: 1782–1788.

51Ni XG, Zhang QQ, Zhu JQ, Wang GO: Hypopharyngeal cancer associated with synchronous oesophageal cancer: risk factors and benefits of image-enhanced endoscopic screening. J Laryngol Otol 2018; 132: 134–161.

52Sato K, Kubota A, Furukawa M, et al: Definitive radiotherapy for early-stage hypopharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol 2015; 272: 2001–2006.

53Chang CC, Chung YH, Liou CB, et al: Influence of residential environment and lifestyle on multiple primary malignancies in Taiwan. Asian Pac J Cancer Prev 2015; 16: 3533–3538.

54Jegu J, Binder-Foucard F, Borel C, Velten M: Trends over three decades of the risk of second primary cancer among patients with head and neck cancer. Oral Oncol 2013; 49: 9–14.

Patrick J. Bradley, MBA FRCS

Department of Otolaryngology, Head and Neck Surgery

Nottingham University Hospital NHS Trust, Queens Medical Centre Campus

Derby Road, Nottingham NG7 2UH (UK)

E-Mail pjbradley@zoo.co.uk